GlassScriptPhysician profile
Debra F Morrison
NPI 1992709836
$4,561.15
in general payments reported to CMS, 2019-2025
15 companies · $843 in 2025
The $843 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2020: $319 · 2021: $271 · 2022: $638 · 2023: $1,031 · 2024: $1,284 · 2025: $843.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,058 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,058.32 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,548.62 | 2019-2025 | |
| Pfizer INC. | $241.26 | 2019-2025 | |
| Janssen Biotech, INC. | $147.85 | 2021-2025 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $125.64 | 2019-2025 | Xifaxan |
| Janssen Scientific Affairs, LLC | $104.98 | 2020 | |
| Aimmune Therapeutics, INC. | $79.54 | 2024 | |
| Genzyme Corporation | $76.45 | 2022-2024 | |
| Celgene Corporation | $75.27 | 2023 | Zeposia |
| Micro-Tech Endoscopy USA, INC. | $44.63 | 2025 | Riteclip |
| Regeneron Healthcare Solutions, INC. | $32.67 | 2023 | Dupixent |
| Amgen INC. | $29.60 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $22.81 | 2025 | Iqirvo |
| Takeda Pharmaceuticals U.S.A., INC. | $18.30 | 2023 | Entyvio |
| Intercept Pharmaceuticals, INC. | $13.53 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$38,544.56 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Morrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.